Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis

Journal Title: UNKNOWN - Year 2017, Vol 23, Issue 4

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system and is characterized by inflammation, demyelination, and axonal loss. Fingolimod is the first oral drug for the treatment of MS approved by the United States Food and Drug Administration, European Union countries, and various other countries. The compound exerts its effect via interaction with lysophospholipid receptors known as sphingosine-1 phosphate receptors. Although fingolimod has a very convenient daily oral dosing, it may cause development of bradycardia at the first dose, macular edema, infection, all of which require attention. Randomized double-blind clinical trials have shown that fingolimod significantly reduces relapse rates and is beneficial in brain magnetic resonance imaging measures when compared with both placebo and intramuscular interferon β-1a. This review describes the characteristics of fingolimod concerning its efficacy, safety, and tolerability in the clinical context of the management of MS.

Authors and Affiliations

Burcu Altunrende, Erkingül Birday, Mithat Kasap, Gülşen Akman Demir

Keywords

Related Articles

Clinical and Demographic Features of Pseudotumor Cerebri Syndrome Diagnosed in a University Hospital

Objective: Pseudotumor cerebri syndrome (PTCS) is characterized by symptoms and signs of increased intracranial pressure without ventriculomegaly, intracranial tumor or mass. This study aimed to explore and analyze 34 pa...

Paraneoplastic Neurologic Syndromes: Rare But More Common Than Expected Nine Cases with a Literature Review

Paraneoplastic neurologic syndromes (PNS) are rare disorders, which are remote effects of cancer that are not caused by the tumor, its metastasis or side effects of treatment. We had nine patients with PNS; two of our pa...

Assessment of Trunk Control in Patients with Neuromuscular Diseases: Validity and Reliability of the Trunk Impairment Scale

Objective: The aim of our study was to determine the reliability and validity of the Trunk Impairment Scale (TIS) in patients with adult neuromuscular diseases (NMD). Materials and Methods: Sixty-six patients with NMD pa...

Download PDF file
  • EP ID EP276790
  • DOI 10.4274/tnd.62144
  • Views 83
  • Downloads 0

How To Cite

Burcu Altunrende, Erkingül Birday, Mithat Kasap, Gülşen Akman Demir (2017). Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis. UNKNOWN, 23(4), 176-185. https://www.europub.co.uk/articles/-A-276790